Previous immune checkpoint inhibitor therapy is associated with decreased COVID-19-related hospitalizations and complications in patients with cancer: Results of a propensity-matched analysis of the OnCovid registry.

Objectives: To date, studies have not provided definitive answers regarding whether previous immune checkpoint inhibitor (ICI) treatment alters outcomes for cancer patients with COVID-19. Methods: The OnCovid registry (NCT04393974) was searched from February 27, 2020, to January 31, 2022, for patien...

Descripción completa

Detalles Bibliográficos
Autores: Mostaghim, Anahita, Minkove, Samuel, Aguilar Company, Juan, Ruiz, Isabel (Ruiz Camps), Eremiev-Eremiev, Simeon, Dettorre, Gino M., Fox, Laura, Tondini, Carlo, Brunet, Joan, Carmona-García, M. Carmen, Lambertini, Matteo, Bower, Mark, Newsom-Davis, Tom, Sharkey, Rachel, Pria, Alessia dalla, Rossi, Maura, Plaja, Andrea, Salazar Soler, Ramón, Sureda, Anna, Prat Aparicio, Aleix, Michalarea, Vasiliki, Hemelrijck, Mieke Van, Sita-Lumsden, Ailsa, Bertuzzi, Alexia, Rimassa, Lorenza, Rossi, Sabrina, Rizzo, Gianpiero, Pedrazzoli, Paolo, Lee, Alvin J. X., Murphy, Cian, Belessiotis, Katherine, Diamantis, Nikolaos, Mukherjee, Uma, Pommeret, Fanny, Stoclin, Annabelle, Martinez-Vila, Clara, Bruna, Riccardo, Gaidano, Gianluca, D’Avanzo, Francesca, Gennari, Alessandra, Athale, Janhavi, Eichacker, Peter, Pinato, David J., Torabi-Parizi, Parizad, Cortellini, Alessio, OnCovid study group
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2024
País:España
Institución:Universidad de Barcelona
Repositorio:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/213448
Acceso en línea:https://hdl.handle.net/2445/213448
Access Level:acceso abierto
Palabra clave:COVID-19
Immunoteràpia
Càncer
SARS-CoV-2
Immunotheraphy
Cancer
Descripción
Sumario:Objectives: To date, studies have not provided definitive answers regarding whether previous immune checkpoint inhibitor (ICI) treatment alters outcomes for cancer patients with COVID-19. Methods: The OnCovid registry (NCT04393974) was searched from February 27, 2020, to January 31, 2022, for patients who received systemic anti-cancer therapy in the 4 weeks before laboratory-confirmed COVID-19 diagnosis. Propensity-score matching using country, vaccination status, primary tumor type, sex, age, comorbidity burden, tumor stage, and remission status investigated differences in predefined clinical outcomes comparing those who had or had not received ICIs. Results: Of 3523 patients screened, 137 ICI-only and 1378 non-ICI met inclusion criteria. Before matching, ICI patients were older, male, enrolled at centers in Italy, and had histories of smoking, thoracic cancers, advanced cancer stages, and active malignancies (P ≤0.02). After matching, there were 120 ICI and 322 non-ICI patients. ICI patients had no differences (odds ratio: 95% CI) in presenting COVID-19 symptoms (0.69: 0.37-1.28), receipt of COVID-specific therapy (0.88: 0.54-1.41), 14-day (0.95: 0.56-1.61), or 28-day (0.79: 0.48-1.29) mortalities. However, ICI patients required less COVID-19-related hospitalization (0.37: 0.21-0.67) and oxygen therapy (0.51: 0.31-0.83) and developed fewer complications (0.57: 0.36-0.92). Conclusion: In this propensity-score matched analysis, previous ICI therapy did not worsen and potentially improved COVID-19 outcomes in patients with cancer.

Similares en LA Referencia